to form two-chain tPA [ 1 ]. Reteplase (recombinant plasminogen activator, rPA) is a thrombolytic agent approved by the Food and Drug Administration ( http://en.wikipedia.org/wiki/Food_and_Drug_ Administration ) in 1996 for the management of acute myocardial infarction (AMI) in adults, in the reduction of the incidence of congestive heart failure, and for